美国老年退伍军人中单独接种肺炎球菌疫苗与双联接种的比较有效性
该回顾性队列研究纳入2014至2016年间美国退伍军人健康管理局的1,277,575人,比较PCV13、PPSV23及双联接种对肺炎球菌肺炎和脑膜炎的效果。与PPSV23相比,PCV13与肺炎球菌肺炎风险降低相关(调整HR 0.69),双联接种亦与肺炎球菌肺炎风险降低相关(调整HR 0.88);脑膜炎结局无显著差异。
要点
- 与PPSV23相比,PCV13与肺炎球菌肺炎风险降低相关(调整HR 0.69;95%CI 0.51-0.93)。
- 双联接种较PPSV23与肺炎球菌肺炎风险降低相关(调整HR 0.88;95%CI 0.77-0.99;P=0.03)。
- PCV13与PPSV23在肺炎球菌脑膜炎和其他脑膜炎上无显著差异。
核心结论
- 与PPSV23相比,PCV13与老年退伍军人肺炎球菌肺炎发生率降低31%相关,该临床获益结果与最新指南推荐所有老年人常规接种肺炎球菌结合疫苗一致。
研究设计与样本
- 2014至2016年间在退伍军人健康管理局(VHA)开展的回顾性队列研究,样本量N=1,277,575。
主要发现
- 与PPSV23相比,PCV13与肺炎球菌肺炎风险降低相关(调整HR 0.69;95%CI 0.51-0.93),与其他肺炎风险降低相关(调整HR 0.74;95%CI 0.64-0.86)。
- PCV13与PPSV23在肺炎球菌脑膜炎(调整HR 3.98;95%CI 0.74-21.32;P=0.12)和其他脑膜炎(调整HR 0.81;95%CI 0.33-2.03;P=0.66)上无显著差异。
- 与PPSV23相比,双联接种与肺炎球菌肺炎发生率降低相关(调整HR 0.88;95%CI 0.77-0.99;P=0.03),与其他肺炎发生率降低相关(调整HR 0.90;95%CI 0.85-0.95;P<0.01)。
临床怎么用
- 作者指出,其显示PCV13接种临床获益的结果与最新肺炎球菌疫苗接种指南推荐所有老年人常规接种肺炎球菌结合疫苗一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pneumococcal vaccination recommendations are constantly evolving. Recent pneumococcal vaccination guidelines have been updated to recommend pneumococcal conjugate vaccines in older adults. However, the clinical benefits of protein conjugate vaccine (PCV 13), pneumococcal polysaccharide vaccine (PPSV 23) and dual vaccination when compared to each other remain unclear. METHODS: A retrospective cohort study conducted between 2014 and 2016 conducted at the Veterans Health administration (VHA) (N = 1,277,575). Primary outcomes were pneumococcal pneumonia and pneumococcal meningitis. Secondary outcomes were "other" pneumonia and "other" meningitis. "Other" referred to episodes of pneumonia and meningitis without an identified etiological agent. RESULTS: PCV 13 was associated with decreased risk of pneumococcal pneumonia (Adjusted HR 0.69; 95 % CI 0.51 to 0.93) and "other" pneumonia (Adjusted HR 0.74; 95 % CI 0.64 to 0.86) when compared to PPSV 23. No significant difference was found between PCV 13 and PPSV 23 in terms of pneumococcal meningitis (Adjusted HR 3.98; 95 % CI 0.74 to 21.32; P = 0.12) and "other" meningitis (Adjusted HR 0.81; 95 % CI 0.33 to 2.03; P = 0.66). Dual vaccination was also associated with a decrease in the rate of pneumococcal pneumonia (Adjusted HR 0.88; 95 % CI 0.77 to 0.99; P = 0.03) and "other" pneumonia (Adjusted HR 0.90; 95 % CI 0.85 to 0.95; P < 0.01) in comparison to PPSV 23. CONCLUSIONS: PCV 13 was associated with a 31% decrease in the rate of pneumococcal pneumonia in comparison to PPSV 23 in older adult Veterans. Our results demonstrating clinical benefit with PCV 13 vaccination are in alignment with the latest pneumococcal vaccination guidelines that recommend routine vaccination with pneumococcal conjugate vaccines in all older adults.
引用
- Narsingam S, Munson J, Drescher F, et al. Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans. Vaccine. 2022. PMID: 35927134. doi:10.1016/j.vaccine.2022.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。